Cargando…

Drug Disposition in the Lower Gastrointestinal Tract: Targeting and Monitoring

The increasing prevalence of colonic diseases calls for a better understanding of the various colonic drug absorption barriers of colon-targeted formulations, and for reliable in vitro tools that accurately predict local drug disposition. In vivo relevant incubation conditions have been shown to bet...

Descripción completa

Detalles Bibliográficos
Autores principales: Lemmens, Glenn, Van Camp, Arno, Kourula, Stephanie, Vanuytsel, Tim, Augustijns, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7912393/
https://www.ncbi.nlm.nih.gov/pubmed/33530468
http://dx.doi.org/10.3390/pharmaceutics13020161
_version_ 1783656567238819840
author Lemmens, Glenn
Van Camp, Arno
Kourula, Stephanie
Vanuytsel, Tim
Augustijns, Patrick
author_facet Lemmens, Glenn
Van Camp, Arno
Kourula, Stephanie
Vanuytsel, Tim
Augustijns, Patrick
author_sort Lemmens, Glenn
collection PubMed
description The increasing prevalence of colonic diseases calls for a better understanding of the various colonic drug absorption barriers of colon-targeted formulations, and for reliable in vitro tools that accurately predict local drug disposition. In vivo relevant incubation conditions have been shown to better capture the composition of the limited colonic fluid and have resulted in relevant degradation and dissolution kinetics of drugs and formulations. Furthermore, drug hurdles such as efflux transporters and metabolising enzymes, and the presence of mucus and microbiome are slowly integrated into drug stability- and permeation assays. Traditionally, the well characterized Caco-2 cell line and the Ussing chamber technique are used to assess the absorption characteristics of small drug molecules. Recently, various stem cell-derived intestinal systems have emerged, closely mimicking epithelial physiology. Models that can assess microbiome-mediated drug metabolism or enable coculturing of gut microbiome with epithelial cells are also increasingly explored. Here we provide a comprehensive overview of the colonic physiology in relation to drug absorption, and review colon-targeting formulation strategies and in vitro tools to characterize colonic drug disposition.
format Online
Article
Text
id pubmed-7912393
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79123932021-02-28 Drug Disposition in the Lower Gastrointestinal Tract: Targeting and Monitoring Lemmens, Glenn Van Camp, Arno Kourula, Stephanie Vanuytsel, Tim Augustijns, Patrick Pharmaceutics Review The increasing prevalence of colonic diseases calls for a better understanding of the various colonic drug absorption barriers of colon-targeted formulations, and for reliable in vitro tools that accurately predict local drug disposition. In vivo relevant incubation conditions have been shown to better capture the composition of the limited colonic fluid and have resulted in relevant degradation and dissolution kinetics of drugs and formulations. Furthermore, drug hurdles such as efflux transporters and metabolising enzymes, and the presence of mucus and microbiome are slowly integrated into drug stability- and permeation assays. Traditionally, the well characterized Caco-2 cell line and the Ussing chamber technique are used to assess the absorption characteristics of small drug molecules. Recently, various stem cell-derived intestinal systems have emerged, closely mimicking epithelial physiology. Models that can assess microbiome-mediated drug metabolism or enable coculturing of gut microbiome with epithelial cells are also increasingly explored. Here we provide a comprehensive overview of the colonic physiology in relation to drug absorption, and review colon-targeting formulation strategies and in vitro tools to characterize colonic drug disposition. MDPI 2021-01-26 /pmc/articles/PMC7912393/ /pubmed/33530468 http://dx.doi.org/10.3390/pharmaceutics13020161 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Lemmens, Glenn
Van Camp, Arno
Kourula, Stephanie
Vanuytsel, Tim
Augustijns, Patrick
Drug Disposition in the Lower Gastrointestinal Tract: Targeting and Monitoring
title Drug Disposition in the Lower Gastrointestinal Tract: Targeting and Monitoring
title_full Drug Disposition in the Lower Gastrointestinal Tract: Targeting and Monitoring
title_fullStr Drug Disposition in the Lower Gastrointestinal Tract: Targeting and Monitoring
title_full_unstemmed Drug Disposition in the Lower Gastrointestinal Tract: Targeting and Monitoring
title_short Drug Disposition in the Lower Gastrointestinal Tract: Targeting and Monitoring
title_sort drug disposition in the lower gastrointestinal tract: targeting and monitoring
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7912393/
https://www.ncbi.nlm.nih.gov/pubmed/33530468
http://dx.doi.org/10.3390/pharmaceutics13020161
work_keys_str_mv AT lemmensglenn drugdispositioninthelowergastrointestinaltracttargetingandmonitoring
AT vancamparno drugdispositioninthelowergastrointestinaltracttargetingandmonitoring
AT kourulastephanie drugdispositioninthelowergastrointestinaltracttargetingandmonitoring
AT vanuytseltim drugdispositioninthelowergastrointestinaltracttargetingandmonitoring
AT augustijnspatrick drugdispositioninthelowergastrointestinaltracttargetingandmonitoring